SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is a focal point of discussion as a prominent influencer's audacious "three-digit" price prediction by year-end approaches its unfulfilled deadline, sparking considerable community mockery and frustration. Amidst this sentiment, traders are also discussing the upcoming monthly token unlock and anticipating potential catalysts like the Clarity Act in the coming year, while deeply divided on whether institutional interest signals an imminent supply shock or continued price manipulation.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Crypto ($SAILANA) is actively trending as its 'Wolfpack' community rallies around the recently launched WolfSWAP, a cross-chain aggregator that facilitates token swaps and offers fee-sharing opportunities for other projects. Community members are enthusiastically discussing this innovative utility and anticipating a future 'flagship product' that they believe will establish Sailana as a leading, decentralized memecoin.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

GBTC is trending as the crypto community intensely debates Bitcoin's near-term future, with many anticipating a "crypto winter" and substantial declines based on historical cycles. Conversely, a significant portion argues that institutional adoption and shifting market dynamics signal undervaluation and an impending "parabolic" rally. This sharp divergence underscores ongoing uncertainty about Bitcoin's valuation and whether traditional patterns will hold, making GBTC a focal point in the contrasting outlooks for digital assets.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending as the crypto market experiences notable outflows from Bitcoin ETFs, fueling a contentious community debate. A significant portion warns of an impending "crypto winter" and further declines, referencing past cycles and the absence of a blow-off top. Conversely, others maintain a long-term bullish stance, citing Bitcoin's historical resilience and sustained institutional interest.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amidst a polarized community debate on Bitcoin's price trajectory, with market participants closely watching the upcoming Bank of Japan rate decision as a key catalyst. Many are actively discussing whether Bitcoin has entered a 'crypto winter,' citing historical cycles and portraying recent price movements as opportunities for large holders to exit, while others highlight sustained institutional interest and ETF inflows as bullish indicators.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins ($PENGU) is actively trending due to its ambitious real-world integrations, highlighted by its high-profile appearance on the Las Vegas Sphere and partnerships with the NHL, Care Bears, and DreamWorks' Kung Fu Panda. While many in the community are debating significant recent price drops and labeling it a 'scam,' others are accumulating, citing these unique brand collaborations as strong long-term fundamentals that could propel the meme coin higher, particularly with ongoing speculation about a potential ETF approval.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amidst a highly divided community, with proponents highlighting its real-world utility through Flexa partnerships and potential positive impacts from the Clarity Act and rumored mergers. While some anticipate significant upward movement, a vocal segment expresses deep frustration over past performance and skepticism, labeling it a 'scam' due to perceived manipulation and persistent downward pressure.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is surging due to the FDA granting Priority Review for its AXS-05 supplemental New Drug Application for Alzheimer's disease agitation, signaling an accelerated review timeline. This significant regulatory clarity, coupled with positive pre-NDA feedback for AXS-12 in narcolepsy, has ignited widespread excitement among long-term investors. The community is actively discussing the stock's substantial price and volume increase, viewing these developments as a major validation for Axsome's robust CNS pipeline within the dynamic biotech sector.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending significantly due to a strategic manufacturing partnership announcement aimed at scaling production of its drug screening reader for future U.S. market entry. This news, combined with the stock's low float, generated immense trading volume and fueled speculation about a short squeeze. However, community sentiment is highly divided following an after-hours private placement offering with warrants, which introduced dilution concerns after the initial surge.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is a hot topic as the market weighs a significant price drop and the FDA's approval of Novo Nordisk's oral Wegovy, fueling speculation about a distribution partnership. Bulls view current levels as a strong buying opportunity, citing robust subscriber growth and a share buyback program. Meanwhile, bears express concern over valuation, perceived market manipulation, and the company's long-term competitive position in the direct-to-consumer health sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RARE Rises on Completion of Rolling Submission for AAV Gene Therapy

Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.

Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock investors bought 3,801 call options on the stock. This...

Leerink Partners Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $70.00

Leerink Partners reduced their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Tuesday...

Robert W. Baird Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Robert W. Baird decreased their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an "outperform" rating for the company in a research note on Tuesday...

<ul class="summary-bullets"><li>Analysts cut price targets after the Phase 3 miss but largely maintained positive ratings and highlighted secondary endpoint strength.</li><li>The focus has shifted toward Ultragenyx’s broader pipeline and upcoming regulatory and clinical milestones.</li><li>Retail sentiment stayed positive as investors reassessed the magnitude of the selloff.</li></ul><p>Shares of Ultragenyx Pharmaceutical (RARE) surged nearly 12% and were on track for their strongest session in about 17 months on Tuesday, as investors looked past analyst actions following the company’s Phase 3 setback in brittle bone disease.</p><p>The move comes a day after the stock plunged more than 40% when Ultragenyx said its Phase 3 Orbit and Cosmic studies of Setrusumab (UX143) in osteogenesis imperfecta&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-rare-stock-plunge-over-41-percent-today/cL75UoUREx1">did not meet the primary endpoint</a> of reducing annualized fracture rates, though both trials showed improvements in bone mineral density.</p><h2 class="st-heading-2"><strong>JPMorgan Removes Focus List Status</strong></h2><p>At JPMorgan, analyst Anupam Rama removed Ultragenyx from the firm’s Analyst Focus List, saying he was “surprised and disappointed” by the trial outcome. Rama said he expects a sentiment overhang on the shares following the miss and kept an ‘Overweight’ rating.</p><h2 class="st-heading-2"><strong>Wells Fargo: ‘Too Soon To Throw In The Towel’</strong></h2><p>Wells Fargo analyst Benjamin Burnett lowered his price target to $45 from $65 and kept an ‘Overweight’ rating. Burnett said Setrusumab achieved statistical significance on bone mineral density, the secondary endpoint, in both studies and described the stock’s risk-reward as “highly favorable” ahead of potential FDA feedback. He added it was “too soon to throw in the towel,” citing key opinion leader checks indicating bone mineral density is viewed as an objective measure of benefit.</p><h2 class="st-heading-2"><strong>Jefferies Looks To 2026 Pipeline Catalyst</strong></h2><p>At Jefferies, analysts cut their price target on Ultragenyx to $63 from $114 while keeping a ‘Buy’ rating. The firm said the Setrusumab miss sent shares sharply lower but expects a rebound in 2026 as investors position for a Phase 3 readout in Angelman syndrome.</p><h2 class="st-heading-2"><strong>Other Target Cuts Maintain Ratings</strong></h2><p>Barclays lowered its price target to $44 from $50 and kept an ‘Overweight’ rating, citing the failure of the Orbit and Cosmic studies to achieve statistical significance on the primary endpoint.</p><p>Citi cut its target to $50 from $103 and maintained a ‘Buy’ rating, calling the trial failure a “significant surprise” and removing Setrusumab revenue from its model.</p><p>Cantor Fitzgerald reduced its target to $84 from $105 and reiterated an ‘Overweight’ rating.</p><h2 class="st-heading-2"><strong>Pipeline Focus And Cost Cuts</strong></h2><p>Truist analyst Joon Lee said the focus now shifts to Apazunersen for Angelman syndrome, with Phase 3 Aspire topline data expected in the second half of 2026. Lee kept a ‘Buy’ rating with a $90 price target and said his work suggests Apazunersen has a higher probability of success than Setrusumab in osteogenesis imperfecta.</p><p>Ultragenyx also said it will significantly reduce expenses after reviewing planned operations, a step investors appeared to factor into Tuesday’s rebound as attention turned to longer-term pipeline milestones.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Ultragenyx was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:978/140;" src="https://news.stocktwits-cdn.com/rare_ss_png_5e7873d97f.webp" alt="rare ss.png" width="978" height="140"><figcaption>RARE sentiment and message volume as of December 30| Source: Stocktwits</figcaption></figure><p>One bullish user said the stock could trade in the $25–$30 range next.</p><p><stembedurl>https://stocktwits.com/Bullishwizard/message/640411021</stembedurl></p><p>Another user said the recent move looks like a “correction after over reaction,” pointing to Ultragenyx’s FDA-approved portfolio including Dojolvi, Crysvita, and Mepsevii.</p><p><stembedurl>https://stocktwits.com/roaringcharts/message/640407881</stembedurl></p><p><a href="https://stocktwits.com/symbol/RARE">Ultragenyx’s stock</a> has declined 48% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ultragenyx Stock Eyes Best Day In 17 Months As Wall Street Shifts Focus To 2026 Pipeline After Bone Disease Trial Miss

The rally reflects renewed investor attention on longer-term pipeline catalysts and regulatory milestones rather than the recent late-stage trial setback.

Equity

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase - Time to Buy?

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase - Should You Buy...

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint

Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.

Wells Fargo & Company Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $45.00

Wells Fargo & Company cut their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an "overweight" rating for the company in a research note on Tuesday...

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $63.00 by Analysts at Jefferies Financial Group

Jefferies Financial Group cut their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a "buy" rating on the stock in a research note on Tuesday...

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

RARE
Ultragenyx Pharmaceutical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RARE News

RAREUltragenyx Pharmaceutical Inc